KS

Krishnan Sampath

Chief Technology Officer


Key Profile Information



Position and Role


  • Current Title: Chief Technology Officer (CTO) at Invetx.

  • Previous Roles: Senior Vice President (SVP) of CMC and Manufacturing at Invetx.

  • Executive Team: Part of the executive leadership team at Invetx.


Professional Experience


  • Industry Expertise: Over 20 years in biologics CMC (Chemistry, Manufacturing, and Controls) development and manufacturing, focusing on novel biologics and biosimilars.

  • Career Highlights:

  • Pioneered advanced biopharmaceutical techniques for veterinary applications.

  • Led formulation studies that resulted in robust and flexible therapeutic protein formulations.

  • Established a third-party manufacturing network for veterinary monoclonal antibodies under both FDA/EMA and USDA jurisdictions.


Education


  • Institution: University of Colorado Health Sciences Center

  • Field: Health Sciences

  • Additional Certifications: Lean Six Sigma Green Belt from Purdue University.


Notable Achievements


  • Publication Contributions: An author of multiple key publications in the field of pharmaceutical sciences, including journals such as the Journal of Pharmaceutical Sciences and Current Pharmaceutical Biotechnology.

  • Examples:

  • "Roadmap for Drug Product Development and Manufacturing of Biologics."

  • "Rational design of lyophilized high concentration protein formulations."

  • "Physical stability of proteins in solution: Relevance to therapeutic formulations and protein deposition diseases."

  • Professional Recognition: Contributions acknowledged by publications and fellow professionals. Recommended by colleagues for scientific guidance and extensive formulation studies.


Professional Network


  • LinkedIn Connections: Over 500+ professional connections and 3,000 followers.

  • Industry Influence: Active participant in collaborative ventures and strategic partnerships, such as with Dechra Pharmaceuticals for Invetx’s acquisition.


Company Performance and Initiatives


  • Recent Company Milestones:

  • Received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial for JK06.

  • Announced the acquisition by Dechra Pharmaceuticals, valued at up to $520 million.

  • Completed developments in half-life extension technology for monoclonal antibody treatments for canines and felines.

  • Strategic Collaborations:

  • Partnership with Akston Biosciences for innovative companion animal insulin programs.

  • Strategic collaboration with Boehringer Ingelheim to advance monoclonal antibody biotherapeutics in animal health.


Publications and Research Interests


  • Authored comprehensive reviews and articles on formulation and process development strategies for biopharmaceuticals.

  • Contributors to highly regarded pieces on the mechanisms of protein aggregation and stability relevant to therapeutic formulations.


Social Media Activity


  • LinkedIn Engagement: Actively engaged with industry updates and professional insights, sharing pivotal company news and personal professional updates.

  • Publications: Routinely shares and discusses industry advances, particularly in veterinary biotherapeutics and biologics drug development.





Insight for Sales Engagement


Krishnan Sampath's extensive background in biologics development and leadership within Invetx positions him as an influential figure in the biopharmaceuticals space. His active role in industry collaborations and numerous publications underscore his authority and commitment to advancing therapeutic solutions. Engaging with Krishnan should focus on showcasing how new solutions can further enhance Invetx's innovative edge and support ongoing development initiatives, particularly those aligned with personalized and advanced veterinary therapeutics.